Portal de Periódicos da CAPES

Ticagrelor with or without Aspirin in High-Risk Patients after PCI

2019; Massachusetts Medical Society; Volume: 381; Issue: 21 Linguagem: Inglês

10.1056/nejmoa1908419

1533-4406

Roxana Mehran, Usman Baber, Samin K. Sharma, David J. Cohen, Dominick J. Angiolillo, Carlo Briguori, Yichao Jin, Timothy Collier, George Dangas, Dariusz Dudek, Vladimír Džavík, Javier Escaned, Robert Gil, Paul A. Gurbel, Christian W. Hamm, Timothy D. Henry, Kurt Huber, Adnan Kastrati, Upendra Kaul, Ran Kornowski, Mitchell W. Krucoff, Vijay Kunadian, Steven O. Marx, Shamir R. Mehta, David J. Moliterno, E. Magnus Ohman, Keith G. Oldroyd, Gennaro Sardella, Samantha Sartori, Richard Shlofmitz, Philippe Gabríel Steg, Giora Weisz, Bernhard Witzenbichler, Yaling Han, Stuart J. Pocock, C. Michael Gibson,

Coronary Interventions and Diagnostics

Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI).